Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
threats decrease » greatest decrease (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
threats decrease » greatest decrease (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
-
2381
-
2382
Verification of PLUS CYCLE<sup>®</sup> signals during presumed sleep periods.
Published 2025Subjects: -
2383
-
2384
-
2385
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2386
-
2387
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2388
-
2389
-
2390
-
2391
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2392
-
2393
-
2394
-
2395
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2396
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2397
-
2398
-
2399
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2400